Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Pgx Tacrolimus Test
Back to catalog

Pharmacogenomics (PGx) Tacrolimus CYP3A5 Test

A targeted pharmacogenomic test evaluating CYP3A5 metabolizer status to optimize tacrolimus dosing for transplant patients, powered by the Helix Exome+® platform.

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Test Description

Tacrolimus is an immunosuppressant prescribed to patients undergoing organ transplant to reduce risk of organ rejection. Tacrolimus reduces activity of the immune system, leading to reduced risk of organ rejection, specifically for adult patients who have received a kidney, liver, lung, or heart transplant. This drug may also be prescribed to children undergoing organ transplant under specific clinical circumstances.

This test evaluates a patient’s metabolizer status for CYP3A5, which can aid in optimal dosing of tacrolimus to maximize immune suppression efficacy to prevent organ rejection and reduce risk of side effects for transplant patients.

View the complete description of this test
Sample report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

Providing a genetic evaluation to determine whether oral use of tacrolimus can reduce risk of organ rejection for transplant patients.

Methodology

This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP3A5. These results are used to determine drug considerations for Tacrolimus.

Technical Specifications

Reportable rangeCYP3A5: *1, *3, *6-*9

Genes Tested

CYP3A5

Showing 1 of 1 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Important Test Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

Blood concentrations and metabolism of tacrolimus are impacted by an individual’s CYP3A5 genotype. This information can help determine appropriate dosing in order to reduce risk of organ rejection leading to improved clinical outcomes for transplant patients.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.